Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEGF-A polymorphisms as predictors of bevacizumab efficacy in advanced breast cancer
ChiCTR-RCS-13003158Phase 2Completed
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- May 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in breast cancer, sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: VEGF gene polymorphism. Started May 2013; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-RCS-13003158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-RCS-13003158.